stars 1 stars 2 stars 3

Biokinetica Early Phase Institute is a specialized clinical research unit conducting early phase studies in both healthy volunteers and patient populations. We are a trusted partner to leading CROs, as well as pharmaceutical and biotechnology companies, recognized for our high-quality clinical services, rapid patient recruitment, and flexible, tailor-made solutions that work. Our team of experienced medical professionals is fully committed to participant safety, regulatory compliance, and flawless study execution to deliver consistent and reliable results. Biokinetica maintains an operational hub at the campus of the Academic Hospital Groningen in the Netherlands and operates an FDA-inspected, hospital-based, state-of-the-art Phase I Unit in the Warsaw area, Poland. Learn more at biokinetica.com/en. See the virtual tour of our clinic: https://youtu.be/9ZpKQQiP2ZI

Biokinetica Questions

The Biokinetica annual revenue was $6.6 million in 2026.

Marek Kiecana is the President and CEO of Biokinetica.

17 people are employed at Biokinetica.

The NAICS codes for Biokinetica are [62, 621, 62151, 6215].

The SIC codes for Biokinetica are [80, 807].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users